iSpecimen Inc. (ISPC) Balance Sheet

NASDAQ: ISPCAssets, liabilities, debt and equity over 8 years.

ISPC balance sheet, 2025

December 31, 2025 · U.S. dollars

$9.5M assets = $6.4M liabilities + $3.1M equity

What it owns$9.5MCash & ST investments: $6.9M (72.2%)Cash & ST investments$6.9M · 72%Receivables: $48,298 (0.5%)Other current: $25,457 (0.3%)PP&E: $294,703 (3.1%)Goodwill & intangibles: $1.0M (10.5%)$1.0MOther non-current: $1.3M (13.5%)Other non-current$1.3M · 13%=How it is financed$9.5MCurrent liabilities: $6.2M (65.4%)Current liabilities$6.2M · 65%Other LT liabilities: $211,873 (2.2%)Shareholders’ equity: $3.1M (32.4%)Shareholders’ equity$3.1M · 32%

Both columns are drawn to the same scale: what ISPC owns equals what it owes plus shareholders’ equity. Hover a block for its value.

ISPC financial health

Current ratio1.12
Adequate · current assets cover current liabilities 1.12×
Debt / equity0.09
Low leverage · $0.09 of debt for each $1 of equity
Equity / assets32.4%
Balanced · of assets funded by shareholders
Cash / debt2,559.9%
Cash covers debt · cash & short-term investments vs total debt
Goodwill & intangibles10.5%
Mostly tangible · of total assets

Descriptive bands, not a rating. Fiscal 2025.

ISPC balance sheet trends, 2018–2025

iSpecimen Inc. balance sheet trends
MetricTrendThenLatestChange
Total assets$4.0M2018$9.5M2025+13.0%/yr
Total liabilities$22.5M2018$6.4M2025−16.3%/yr
Shareholders’ equity−$18.4M2018$3.1M2025—
Cash & short-term investments$1.1M2018$6.9M2025+29.4%/yr
Total debt$7.0M2018$268,7982025−37.2%/yr
Net cash (debt)−$5.8M2018$6.6M2025+$12.5M
Working capital−$9.0M2018$723,2842025+$9.7M
Current ratio0.2020181.122025+0.91
Debt / equity0.1120210.092025−0.03

Change is the average annual growth (CAGR) or the difference between the first and latest year.

ISPC assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

ISPC liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

ISPC debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

ISPC balance sheet

iSpecimen Inc. annual balance sheet
20252024202320222021202020192018
Assets
Cash & short-term investments$6.9M$1.9M$5.0M$15.3M$27.7M$695,909$53,893$1.1M
Cash & equivalents$6.9M$1.9M$2.3M$15.3M$27.7M$695,909$53,893$1.1M
Short-term investments—$0$2.7M$0————
Receivables$48,298$1.4M$2.9M$3.9M$4.9M$2.4M$1.4M$1.0M
Inventory$0$45,110$0$1−$3.0M$0$54,908$47,287
Other current assets$25,457$219,782$292,078$441,306$3.3M$417,929$79,227$100,018
Total current assets$7.0M$3.6M$8.2M$19.7M$32.9M$3.5M$1.6M$2.3M
Property, plant & equipment (net)$294,703$421,540$321,644$410,544$32,781$75,589$119,921$149,098
Goodwill & intangible assets$1.0M$5.3M$7.2M$4.5M$2.7M$2.6M$2.3M$1.4M
Long-term investments$0$0$0$0$0$0$0$0
Other non-current assets$1.3M$12,100$27,602$27,601$27,601$27,601$207,123$154,601
Total assets$9.5M$9.4M$15.8M$24.6M$35.7M$6.2M$4.2M$4.0M
Liabilities
Accounts payable$5.4M$4.2M$3.9M$2.5M$832,678$1.8M$737,794$696,912
Short-term debt$56,925$43,369$167,114$158,451—$12.6M$10.6M$7.0M
Deferred revenue$192,535$360,708$415,771$132,335$654,746$873,254$2.2M$864,915
Total current liabilities$6.2M$5.8M$6.0M$4.3M$2.5M$22.1M$15.8M$11.3M
Long-term debt$0$0$0$0$3.4M$178,899$0$0
Lease obligations$268,798$312,167$196,244$185,847$0———
Other long-term liabilities$211,873$268,798$29,130$27,396$0$11.2M$11.2M$11.2M
Total liabilities$6.4M$6.0M$6.1M$4.3M$5.9M$33.5M$26.9M$22.5M
Shareholders' equity
Common stock & paid-in capital$848$170$908$892$873$94$537$537
Retained earnings (deficit)−$82.4M−$71.9M−$59.4M−$48.3M−$38.0M−$29.1M−$24.4M−$19.7M
Accumulated other comprehensive income——$840$0$0$0$0−$159,829
Total shareholders' equity$3.1M$3.3M$9.7M$20.3M$29.8M−$27.3M−$22.7M−$18.4M
Key figures
Total debt$268,798$312,167$196,244$185,847$3.4M$12.8M$10.6M$7.0M
Net cash (debt)$6.6M$1.6M$4.8M$15.1M$24.3M−$12.1M−$10.5M−$5.8M
Working capital$723,284−$2.2M$2.2M$15.4M$30.4M−$18.7M−$14.2M−$9.0M
Tangible book value$2.1M−$2.0M$2.5M$15.8M$27.1M−$29.9M−$25.0M−$19.9M
Current ratio1.120.621.364.6013.150.160.100.20
Quick ratio1.110.581.314.4913.020.140.090.19
Debt / equity0.090.090.020.010.11———
Equity / assets32.4%35.4%61.6%82.5%83.4%−439.3%−539.1%−455.5%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed April 1, 2026); data from EODHD.

ISPC financial position

At the end of fiscal 2025 (December 31, 2025), iSpecimen had total assets of $9.5 million (up 1.9% from a year earlier), total liabilities of $6.4 million and shareholders' equity of $3.1 million. It held $6.9 million in cash and short-term investments against $0.3 million of debt, a net cash position of $6.6 million. Its current ratio was 1.12. In the latest quarter (ended June 30, 2026) total assets were $7.4 million and equity $1.7 million.

Related: ISPC income statement, ISPC cash flow statement, ISPC key metrics. See the ISPC stock overview for the latest quote and news.

ISPC balance sheet FAQ

What are iSpecimen's total assets?

iSpecimen reported total assets of $9.5 million at the end of fiscal 2025 (December 31, 2025), compared with $9.4 million a year earlier.

How much debt does iSpecimen have?

iSpecimen had $0.3 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.09.

How much cash does iSpecimen have?

iSpecimen held $6.9 million in cash and short-term investments at the end of fiscal 2025; with $0.3 million of debt that is net cash of $6.6 million.

What is iSpecimen's book value?

iSpecimen's shareholders' equity (book value) was $3.1 million at the end of fiscal 2025.

What is iSpecimen's current ratio?

iSpecimen had current assets of $7.0 million and current liabilities of $6.2 million, a current ratio of 1.12 (it can cover its short-term obligations).

How much goodwill does iSpecimen have?

iSpecimen carried $1.0 million of goodwill and intangible assets, 10.5% of total assets, at the end of fiscal 2025.

Diagnostics & Research: balance sheet